Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Adult-Onset Active and Progressive Psoriatic Arthritis (PsA)

Next Previous
Search
Trial Profile

Phase 3, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Adult-Onset Active and Progressive Psoriatic Arthritis (PsA)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Psoriatic arthritis
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms RAPID-PsA
  • Sponsors Schwarz BioSciences; UCB

Most Recent Events

  • 09 Nov 2021 Results evaluating the association between DAPSA disease states and burden on paid/household work productivity in patients with PsA during long-term treatment with Certolizumab , presented at the ACR Convergence 2021
  • 19 Nov 2020 Results of an analysis assessing the association between improvements in clinical outcomes and burden on work productivity presented at the 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
  • 06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top